Baidu
map

Asian Pac J Allergy Immunol:中国过敏性鼻炎与哮喘并发流行度分析

2018-12-26 AlexYang MedSci原创

过敏性鼻炎(AR)和哮喘是呼吸道最常见的炎症疾病。哮喘与AR的关系已经有很广泛的研究。"One airway, one disease"的概念已经被逐渐的接受。然而,在中国还没有对AR携带哮喘和哮喘携带AR的流行度进行系统的回顾和元分析。最近,有研究人员对所有已经发表达的研究结果进行了元分析,并呈现中国AR携带哮喘和哮喘携带AR并发比例的确定信息。研究人员对各大数据Pubmed/Medline、S

过敏性鼻炎(AR)和哮喘是呼吸道最常见的炎症疾病。哮喘与AR的关系已经有很广泛的研究。"One airway, one disease"的概念已经被逐渐的接受。然而,在中国还没有对AR携带哮喘和哮喘携带AR的流行度进行系统的回顾和元分析。

最近,有研究人员对所有已经发表达的研究结果进行了元分析,并呈现中国AR携带哮喘和哮喘携带AR并发比例的确定信息。研究人员对各大数据Pubmed/Medline、Science、Springer、Elsevier、Embase、Wanfang data、VIP、CBM和CNKI进行了系统的搜索,并利用Stata12.1软件对元分析、研究质量评估和出版偏好进行了评估。研究发现,元分析结果显示AR携带哮喘的合并流行度范围为6.69%到14.35%,哮喘携带AR的范围为26.67%到54%。更多的是,AR携带哮喘的总流行度为10.17%(95% CI 9.08-11.27%),哮喘携带AR的总流行度为38.97%(95% CI 34.42-43.53%)。

最后,研究人员指出,他们的元分析为AR携带哮喘和哮喘携带AR提供了综合的首次定量总结。研究人员还认为他们的研究阐释了在中国,哮喘和AR总是并发疾病和共存的。从流行病学角度来看,AR和哮喘具有紧密的联系。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780099, encodeId=65541e80099c0, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Oct 07 23:51:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651442, encodeId=a31e1651442ee, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Sat Feb 23 22:51:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758064, encodeId=51f71e580645e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 19 17:51:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956452, encodeId=759d195645217, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Jul 30 21:51:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047056, encodeId=52ba204e056d2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Mar 31 15:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329189, encodeId=169a1329189ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 28 05:51:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
    2019-10-07 luwei00
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780099, encodeId=65541e80099c0, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Oct 07 23:51:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651442, encodeId=a31e1651442ee, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Sat Feb 23 22:51:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758064, encodeId=51f71e580645e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 19 17:51:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956452, encodeId=759d195645217, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Jul 30 21:51:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047056, encodeId=52ba204e056d2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Mar 31 15:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329189, encodeId=169a1329189ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 28 05:51:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780099, encodeId=65541e80099c0, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Oct 07 23:51:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651442, encodeId=a31e1651442ee, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Sat Feb 23 22:51:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758064, encodeId=51f71e580645e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 19 17:51:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956452, encodeId=759d195645217, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Jul 30 21:51:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047056, encodeId=52ba204e056d2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Mar 31 15:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329189, encodeId=169a1329189ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 28 05:51:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
    2019-08-19 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780099, encodeId=65541e80099c0, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Oct 07 23:51:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651442, encodeId=a31e1651442ee, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Sat Feb 23 22:51:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758064, encodeId=51f71e580645e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 19 17:51:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956452, encodeId=759d195645217, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Jul 30 21:51:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047056, encodeId=52ba204e056d2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Mar 31 15:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329189, encodeId=169a1329189ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 28 05:51:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780099, encodeId=65541e80099c0, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Oct 07 23:51:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651442, encodeId=a31e1651442ee, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Sat Feb 23 22:51:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758064, encodeId=51f71e580645e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 19 17:51:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956452, encodeId=759d195645217, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Jul 30 21:51:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047056, encodeId=52ba204e056d2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Mar 31 15:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329189, encodeId=169a1329189ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 28 05:51:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1780099, encodeId=65541e80099c0, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Oct 07 23:51:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651442, encodeId=a31e1651442ee, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Sat Feb 23 22:51:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758064, encodeId=51f71e580645e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 19 17:51:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956452, encodeId=759d195645217, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Jul 30 21:51:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047056, encodeId=52ba204e056d2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Mar 31 15:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329189, encodeId=169a1329189ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 28 05:51:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
    2018-12-28 膀胱癌

相关资讯

Allergy Asthma Clin Immunol:中国北方一个乡村地区过敏性和非过敏性鼻炎流行度分析

大多数流行病学研究报道过敏性鼻炎(AR)和非过敏性鼻炎(NAR)时只评估了自我报道的流行度,并没有进行客观的测量确定。更多的是,关于中国人口的NAR流行度报道非常少见。因此,最近有研究人员探索了中国人口中AR和NAR的流行度和风险因子,且主要基于临床表现和过敏状态。研究人员进行的是一个基于群体的代表性调查,包括了中国北京的1084名当地居民。研究发现,自我报道的AR流行度为46.8%。基于SPT结

J Allergy Clin Immunol Pract:柳杉花粉SLIT药片的长期效果和剂量测试试验

在日本,柳杉(JC)花粉症是一种用常见的过敏性鼻炎。JC花粉SLIT药片是使用高浓度的的JC花粉提取物制成的。最近,有研究人员进行了一个随机的、双盲的和案例对照阶段2/3试验来调查JC花粉SLIT药片的最优剂量,并且调查了选择剂量情况下3年的效果和安全性,并进行了2年的跟踪调查研究。研究包括了1042名患有JC过敏症的患者(年龄在5-64岁),并随机的分配到4个小组中接受不同的治疗,每天分别接受2

Eur Arch Otorhinolaryngol:经历过敏原特异性免疫治疗过敏性鼻炎患者的味觉评估

最近,有研究人员评估了患有就行过敏性鼻炎(AR)患者在过敏原特异性免疫治疗(AIT)前后的味觉功能情况。研究是一个前瞻性的临床研究,在研究人员所在三级保健医院中进行。研究包括了21名在身体检查、皮刺测试至少HDM过敏原3星级以及接受AIT治疗的诊断为永久性AR的患者。研究同时包括了21名对照参与者,他们也是过敏性鼻炎患者,但是给予的是鼻用皮质类固醇(INS)治疗。研究总共包括了42名参与者,平均年

Toxicol Lett:PM2.5接触能够增加恶化过敏性鼻炎

过敏性鼻炎(AR)是一种常见的慢性炎症疾病,并且对患者的生活质量具有明显的影响。之前的研究表明了PM2.5能够通过表观遗传调控影响儿科AR,但是潜在的机制仍旧不清楚。最近,有研究人员创制了一个小鼠模型,并在PM2.5处理后评估了鼻部症状、病理变化、INF-γ基因启动子的甲基化水平和ERK-DNMT途径的激活情况。研究结果表明,PM2.5能够导致更加严重的AR症状。另外,PM2.5接触在AR组中能够

Int Arch Allergy Immunol:鼻腔内给药IL-27能够减轻鼻过敏性响应和症状

白介素(IL-27)是Th1响应的一个抑制子,并能够抑制炎症响应。在一个哮喘小鼠模型中,IL-27给药能够减少气管肺泡灌洗和气道高反应中的嗜酸性粒细胞数目。然而,是否IL-27给药能够抑制过敏性疾病和过敏性鼻炎的症状仍旧不清楚。因此,有研究人员调查了体内IL-27给药对鼻症状和过敏性鼻炎的影响。研究人员在利用OVA敏感和诱导的小鼠中进行IL-27鼻腔给药试验。研究发现,与对照PBS鼻腔给药相比,鼻

Allergol Immunopathol (Madr):过敏性鼻炎中,B细胞OX40配体与CD4+ T细胞血清总lgE和IL-4水平相关性分析

过敏性鼻炎(AR)是一种经典的Th2调节的疾病,能够引起重要的白介素4、5和13的病理性变化。OX40共刺激分子和它的配体互作参与了Th1/Th2细胞平衡调控的免疫响应。考虑到OX40配体(OX40L)与AR之间相关信息的缺乏,最近,有研究人员调查了OX40配体在B淋巴细胞中的表达。研究包括了20名AR患者和20名健康参与者。研究人员利用电化学发光免疫检测(ECL)技术对总血清lgE水平进行测量,

Baidu
map
Baidu
map
Baidu
map